GX301 / Mediolanum Pharma, Genovax - LARVOL DELTA

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. (PubMed, Cancer Immunol Immunother) - P2 | "Main objective of this study was to comparatively analyse safety and immunological response to three GX301 regimens in metastatic castration-resistant prostate cancer patients with response/disease stability after docetaxel chemotherapy. These data indicate that GX301 cancer vaccine is safe and immunogenic in metastatic castration-resistant prostate cancer patients. Schedules with high number of administrations should be preferred in future studies due to their better immunological outcome."

Clinical • Journal • P2 data • Genito-urinary Cancer • Immunology • Oncology • Prostate Cancer • Solid Tumor • CD8

A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer (clinicaltrials.gov) - P2; N=99; Completed; Sponsor: Laboratoires Leurquin Mediolanum; Active, not recruiting ➔ Completed

Clinical • Trial completion • Genito-urinary Cancer • Immunology • Oncology • Prostate Cancer • Solid Tumor • KLK3